Answer
Carfilzomib, a tetrapeptide epoxyketone proteasome inhibitor, selectively and irreversibly binds to N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core of the 26S proteasome, with little to no activity against other protease classes.
Sources for this answer
- KyprolisAmgen Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 21Document updated
Sources checked